{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:39:18Z","timestamp":1790368758735,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejogrb.2018.03.058","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T02:14:01Z","timestamp":1522203241000},"page":"212-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Hormonal contraceptives and breast cancer: Clinical data"],"prefix":"10.1016","volume":"230","author":[{"given":"Irene","family":"Zolfaroli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Tar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8046-0303","authenticated-orcid":false,"given":"Antonio","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2018.03.058_bib0005","series-title":"United Nations Department of Economic and Social Affairs Population Division. World contraceptive patterns","year":"2013"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2012.102","article-title":"Breast cancer in young women","volume":"9","author":"Narod","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0015","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.ejogrb.2018.03.058_bib0020","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.breast.2015.07.036","article-title":"Management of breast cancer in very young women","volume":"24","author":"Rosenberg","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0025","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s10549-011-1872-9","article-title":"Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer","volume":"131","author":"Collins","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0030","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.breast.2012.08.005","article-title":"Association between common risk factors and molecular subtypes in breast cancer patients","volume":"22","author":"Turkoz","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0306-3356(21)00626-9","article-title":"The royal college of general practitioners' oral contraception study: some recent observations","volume":"11","author":"Kay","year":"1984","journal-title":"Clin Obstet Gynaecol"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.bjc.6603260","article-title":"Oral contraceptive use and cancer. Findings in a large cohort study, 1968\u20132004","volume":"95","author":"Vessey","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0045","first-page":"65","article-title":"A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States)","volume":"8","author":"Hankinson","year":"1997","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0050","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies","volume":"347","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0055","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and the risk of breast cancer","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0060","first-page":"1375","article-title":"Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish women's lifestyle and health cohort study","volume":"11","author":"Kumle","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0065","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-10-0747","article-title":"Oral contraceptive use and breast cancer: a prospective study of young women","volume":"19","author":"Hunter","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0070","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.4065\/81.10.1290","article-title":"Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis","volume":"81","author":"Kahlenborn","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0075","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1055-9965.EPI-13-0298","article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","volume":"22","author":"Gierisch","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0080","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3109\/13625187.2012.715357","article-title":"Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies","volume":"17","author":"Zhu","year":"2012","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0085","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1158\/1055-9965.EPI-13-0944","article-title":"Oral contraceptives and breast cancer risk overall and by molecular subtype among young women","volume":"23","author":"Beaber","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0090","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1158\/0008-5472.CAN-13-3400","article-title":"Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age","volume":"74","author":"Beaber","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0095","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of Breast cancer","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.contraception.2010.11.009","article-title":"Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer","volume":"83","author":"Dinger","year":"2011","journal-title":"Contraception"},{"issue":"2 Pt. 1","key":"10.1016\/j.ejogrb.2018.03.058_bib0105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/AOG.0000000000000356","article-title":"Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland","volume":"124","author":"Soini","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0110","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.31266","article-title":"Progestin-only and combined oral contraceptives and receptor-defined premenopausal Breast cancer risk: the norwegian women and cancer study","author":"Busund","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0115","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1158\/0008-5472.CAN-11-4064","article-title":"Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age","volume":"72","author":"Li","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0120","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ijc.11307","article-title":"x oral contraceptive use and risk of breast cancer by histologic type","volume":"106","author":"Newcomer","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0125","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1001\/jama.289.24.3254","article-title":"Relationship between long durations and different regimens of hormone therapy and risk of breast cancer","volume":"289","author":"Li","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0130","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/ijc.22970","article-title":"Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women","volume":"121","author":"Sweeney","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0135","first-page":"25","article-title":"Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study","volume":"29","author":"Williams","year":"2018","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0140","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ijc.23163","article-title":"The association between oral contraceptive use and lobular and ductal breast cancer in young women","volume":"122","author":"Nyante","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0145","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2013.807","article-title":"Reproductive risk factors and oestrogen\/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry","volume":"110","author":"Work","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0150","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/1471-2407-13-584","article-title":"Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study","volume":"13","author":"Ritte","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0155","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jnci\/djr030","article-title":"Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer","volume":"103","author":"Phipps","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-08-1005","article-title":"Risk factors for triple-negative breast cancer in women under the age of 45 years","volume":"18","author":"Dolle","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0165","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/0008-5472.CAN-09-3460","article-title":"Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study","volume":"70","author":"Ma","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0170","first-page":"283","volume":"100A","author":"International Agency for Research on Cancer","year":"2012"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0175","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/humupd\/dmq022","article-title":"Hormonal contraception and risk of cancer","volume":"16","author":"Cibula","year":"2010","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0180","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group","volume":"25","author":"Brohet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0185","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"94","author":"Narod","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0190","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-005-9051-5","article-title":"Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland","volume":"95","author":"Gronwald","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0195","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1055-9965.EPI-06-0258","article-title":"kConFab Investigators; Ontario Cancer Genetics Network Investigators, Whittemore AS. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50","volume":"15","author":"Haile","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0200","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1055-9965.EPI-08-0396","article-title":"Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1\/2 mutation carriers and noncarriers: results from a population-based study","volume":"17","author":"Lee","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0205","first-page":"1059","article-title":"Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study","volume":"16","author":"Silvera","year":"2005","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0210","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.clbc.2017.10.016","article-title":"Combined hormonal contraceptive use and risk of breast cancer in a population of women with a family history","volume":"18","author":"Grandi","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0215","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ajog.2017.02.002","article-title":"Lifetime cancer risk and combined oral contraceptives: the royal college of general practitioners' oral contraception study","volume":"216","author":"Iversen","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"January (18)","key":"10.1016\/j.ejogrb.2018.03.058_bib0220","article-title":"Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, Breast, and colorectal cancers","author":"Michels","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejogrb.2018.03.058_bib0225","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/01.AOG.0000284446.22251.6e","article-title":"Oral contraceptives and the risk of death from breast cancer","volume":"110","author":"Wingo","year":"2007","journal-title":"Obstet Gynecol"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518301568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518301568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:44:25Z","timestamp":1759556665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211518301568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":45,"alternative-id":["S0301211518301568"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.03.058","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormonal contraceptives and breast cancer: Clinical data","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.03.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}